Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INBX Inhibrx Biosciences	$28.20 +1.1%	$21.24	$10.81 ▼ $28.29	$408.48M	0.24	106,602 shs	77,071 shs
OLMA Olema Pharmaceuticals	$5.46 -1.1%	$4.91	$2.86 ▼ $13.93	$374.74M	1.92	851,056 shs	302,991 shs
VIRI Virios Therapeutics	$4.80 +3.1%	$4.84	$0.13 ▼ $1.04	$92.34M	1.58	1.05 million shs	18,008 shs
ZYBT Zhengye Biotechnology	$9.36 +5.5%	$6.55	$3.50 ▼ $14.30	$441.51M	N/A	307,023 shs	130,876 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INBX Inhibrx Biosciences	+1.75%	+15.40%	+14.92%	+105.60%	+99.71%
OLMA Olema Pharmaceuticals	-3.83%	-0.36%	+10.18%	+3.76%	-51.75%
VIRI Virios Therapeutics	-6.81%	-4.32%	-3.53%	-12.10%	+2,413.51%
ZYBT Zhengye Biotechnology	+1.26%	+32.39%	+61.27%	-4.42%	+886,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INBX Inhibrx Biosciences	1.6354 of 5 stars	0.0	3.0	0.0	4.6	2.1	2.5	0.0
OLMA Olema Pharmaceuticals	1.9378 of 5 stars	3.3	0.0	0.0	0.0	3.8	2.5	0.0
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	339.56% Upside
VIRI Virios Therapeutics	2.00	Hold	$5.00	4.28% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VIRI, OLMA, INBX, and ZYBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INBX Inhibrx Biosciences	$1.40M	291.77	$122.61 per share	0.23	$4.73 per share	5.96
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A
ZYBT Zhengye Biotechnology	$25.53M	17.29	$0.11 per share	85.02	$1.02 per share	9.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INBX Inhibrx Biosciences	$1.69B	-$10.58	N/A	N/A	N/A	N/A	-137.83%	-76.31%	11/13/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	11/11/2025 (Estimated)
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	N/A
ZYBT Zhengye Biotechnology	$1.55M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VIRI, OLMA, INBX, and ZYBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	INBX Inhibrx Biosciences	-$2.92	-$1.85	+$1.07	-$1.85	N/A	$1.30 million
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INBX Inhibrx Biosciences	1.45	4.98	4.98
OLMA Olema Pharmaceuticals	0.01	11.09	11.09
VIRI Virios Therapeutics	N/A	7.27	7.27
ZYBT Zhengye Biotechnology	0.01	1.31	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INBX Inhibrx Biosciences	82.46%
OLMA Olema Pharmaceuticals	91.78%
VIRI Virios Therapeutics	9.05%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
INBX Inhibrx Biosciences	17.09%
OLMA Olema Pharmaceuticals	16.36%
VIRI Virios Therapeutics	12.20%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INBX Inhibrx Biosciences	166	14.49 million	12.01 million	Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

VIRI, OLMA, INBX, and ZYBT Headlines

Recent News About These Companies

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Up 5.3% - What's Next?

August 29 at 4:28 AM | marketbeat.com

Zhengye Biotechnology Holding Ltd trading resumes

August 22, 2025 | msn.com

Zhengye Biotechnology Holding Ltd trading halted, volatility trading pause

August 21, 2025 | msn.com

Zhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen

August 2, 2025 | marketbeat.com

ZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...

July 17, 2025 | wsj.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock News

July 3, 2025 | gurufocus.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

July 3, 2025 | prnewswire.com

ZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron's

July 2, 2025 | barrons.com

ZYBT - Zhengye Biotechnology Holding Ltd Chart - Morningstar

June 27, 2025 | morningstar.comM

Zhengye Biotechnology Holding Ltd

June 21, 2025 | morningstar.comM

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI, OLMA, INBX, and ZYBT Company Descriptions

Inhibrx Biosciences NASDAQ:INBX

$28.20 +0.32 (+1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$28.19 -0.01 (-0.04%)

As of 04:10 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Olema Pharmaceuticals NASDAQ:OLMA

$5.46 -0.06 (-1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$5.44 -0.02 (-0.37%)

As of 04:20 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Virios Therapeutics NASDAQ:VIRI

$4.80 +0.15 (+3.12%)

As of 08/28/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Zhengye Biotechnology NASDAQ:ZYBT

$9.36 +0.49 (+5.52%)

As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time